Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis
ConclusionBased on this pharmacovigilance study, GLP-1RAs, except albiglutide, are associated with pancreatic carcinoma.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Byetta | Cancer & Oncology | Carcinoma | Databases & Libraries | Drugs & Pharmacology | Pancreas | Pancreatic Cancer | Study | Victoza